At KAMBIS, our roots are firmly planted in Thai soil. We take immense pride in being one of the very few 100% Thai-owned and 100% Thai-based medical cannabis facilities that is fully certified for the international market. For us, “Thai-owned” is more than a label; it is a commitment to excellence that bridges our local agricultural heritage with the rigorous demands of global pharmaceutical standards.
We believe that a successful export engine should also be a pillar for its community. By prioritizing a skilled local workforce, we are not just growing plants; we are investing in people. Our mission goes beyond profit – we aim to grow alongside our neighbors, providing stable, high-skilled opportunities in the medical science sector and fostering long-term economic resilience within our region.
Partnering with a fully Thai-owned facility like KAMBIS offers distinct advantages for the global supply chain:
- Operational Agility & Regulatory Alignment: Being 100% local allows us to navigate the Thai regulatory landscape with unmatched speed and precision. We maintain direct, transparent relationships with local authorities, ensuring our GACP and upcoming EU GMP standards are always in perfect alignment with national and international requirements.
- Cultural Agricultural Expertise: We combine centuries of Thai botanical knowledge with modern clinical oversight. This synergy allows us to produce high-purity medical cannabis that reflects our specialized high-touch cultivation techniques.
- Uncompromised Chain of Custody: With no foreign structures, we offer absolute transparency. Our partners can trust in a Seed-to-Sale journey that is entirely managed by a single, dedicated Thai entity.
- Ethical Impact: Our value stays within Thailand. When you partner with KAMBIS, you are directly supporting the development of the Thai medical workforce and a sustainable, ethical industry model.
We remain dedicated to proving that Thai-owned means world-class. We invite our international partners to join us in this journey of community-driven, pharmaceutical-grade innovation.